Search

Your search keyword '"Ostrowska L"' showing total 13 results
Start Over Author "Ostrowska L" Language undetermined
13 results on '"Ostrowska L"'

1. Comparison of diet and physical activity of children and adolescents with patients after cancer treatment

Author

Zapolska, J., Witczak-Sawczuk, K., Maryna Krawczuk-Rybak, Sawicka-Żukowska, M., Smarkusz, J., and Ostrowska, L.

Subjects
Male, Adolescent, lcsh:Public aspects of medicine, Child Health, physical activity, Nutritional Status, lcsh:TX341-641, lcsh:RA1-1270, Feeding Behavior, Vitamins, Dietary Fats, Diet, lcsh:RC963-969, children, Neoplasms, lcsh:Industrial medicine. Industrial hygiene, Dietary Carbohydrates, cancer, Humans, Female, Dietary Proteins, Poland, Child, lcsh:Nutrition. Foods and food supply, Exercise
Abstract

Background. Properly balanced diet and exercise are an essential element of healthy living for children and adolescents. Particular attention should be paid to nutrition and physical activity among juniors after cancer treatment, which is one of the most important elements of the convalescence period. Objective. The aim of the study was a comparative analysis of diet, physical activity of healthy children and adolescents with patients after cancer treatment. Material and methods. The study involved 60 children and adolescents; 30 healthy juniors and 30 patients after treatment for cancer. An analysis of diets based on a 3-day 24-hour nutrition diary. The questionnaire surveyed collected data about participation and physical activity preferences. Statistical program-Statistica 12.0, published by StatSoft, was used to develop the results. Results. Both groups were characterized by increased consumption of proteins and carbohydrates. Insufficient fat intake was shown in comparison with the recommended amounts in all study groups. It was observed that in the group of patients after treatment, vitamins B1, A, E and D intake was higher than in their healthy peers. Determinants of the choice of physical activity among children after cancer treatment was pleasure and fun, while among their healthy peers, aesthetic considerations (taking care of appearance). Conclusions. Children and adolescents after cancer treatmentin a much greater percentage covered of daily intake of nutrients than healthy children, and more willingly spent time on physical activity. Greater interest in physical activity in this group was probably due to previous restrictions related to illness and therapy.

Published
2018

2. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Author

Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C. W., le Roux, Carel W., Ortiz, Violante, Jensen, Christine Bjorn, Wilding, John P. H., Hamann, A, Barakat, A, Blüher, M, Linn, T, DALLE MOLLE, Alberto, Segner, A, Stübler, P, Tosch-Sisting, R, Pacini, F, Santini, F, Marchesini, G, Rotella, Cm, Invitti, C, Vettor, R, Buscemi, S, Raya, Pm, Freijoo, Fc, de Barbará RG, Carraro, R, Bobillo, Er, de la Cuesta, C, Farsang, C, Csaszar, A, Zahorska-Markiewicz, B, Pupek-Musialik, D, Franek, E, Ostrowska, L, Olszanecka-Glinianowicz, M, Lalic, N, Micic, D, Ludvik, B, Paulweber, B, Prager, R, Scheen, A, Van Gaal, L, Astrup, Av, Hermansen, K, Madsbad, S, Rissanen, A, Nieminen, S, Savolainen, M, Krempf, M, Romon, M, Laville, M, Marre, M, Mira, R, Finucane, F, Veenendaal, A, van Berkum, F, Johannsson-Vidarsdóttir, S, Van de Walle, V, Meesters, E, Hjelmesæth, J, Klemsdal, To, Kulseng, B, Bach-Kliegel, B, Laederach, K, Villiger, L, Golay, A, Bilz, S, Sathyapalan, T, Bain, S, Kumar, S, Le Roux CW, Lean, Me, Mcgowan, B, Rehman, T, Wilding, J, Wittert, G, Caterson, I, Proietto, J, Prins, J, Geloneze Neto, B, Gross, Jl, Chacra, Ar, Halpern, A, Suplicy Hde, A, Chow, Fc, Thacker, Hp, Chadha, M, Chandalia, H, Unnikrishnan, A, Kalra, S, Deshpande, N, Shunmugavelu, M, Deshmukh, Vc, Maislos, M, Lieberman, Gs, Shimon, I, Stern, N, Nabriski, D, Karnieli, E, Shehadeh, N, Gonzalez-Galvez, G, Arechavaleta-Granell Mdel, R, Violante Ortiz RM, Franco, Gm, Gurieva, I, Suplotova, La, Troshina, E, Ruyatkina, La, Voychik, Ea, Martsevich, S, Startseva, Ma, Seeber, Me, Badat, A, Ellis, G, Altuntas, Y, Guler, S, Ulgen, E, Delibasi, T, Chetty, T, Hart, R, Janzen, J, Labonte, I, Lau, D, Liutkus, J, O'Keefe, D, Padwal, R, Ransom, Tp, Tytus, R, Weisnagel, Sj, Adler, J, Aqua, K, Aronoff, Sl, Bedel, Gw, Blevins, Tc, Blumenau, J, Brockmyre, Ap, Call, Rs, Canadas, R, Chaykin, Lb, Cohen, K, Conrow, Jk, Davis, Mg, Downey, Hj, Drosman, Sr, Duckor, S, Farmer, H, Farrell, J, Fehnel, S, Finneran, Mp, Forbes, R, Forker, A, Fredrick, M, Fujioka, K, Geller, Sa, Gill, S, Glaser, L, Greco, Sn, Greenway, Fl, Harper, W, Herman, L, Hoekstra, J, Ingebretsen, R, Ison, R, Jain, Rk, Kaplan, R, Kaster, Sr, Haase, Ga, Kerzner, B, Kirstein, Jl, Koltun, W, Krieger, Dr, Lewis, Ce, Madder, R, Marple, Rn, Mcdermott, Ej, Mello, Cj, Miller, Ab, Mullen, J, Nardandrea, J, O'Neil, P, Pi-Sunyer, F, Pucillo, Rm, Rhee, C, Redrick, S, Pardini, A, Rothman, J, Rubino, Dm, Sellers, G, Smith, T, Byars, Wd, Soufer, J, Sussman, Am, Patrick, K, Schramm, El, Van Cleeff, M, Berg, Sr, Wyatt, Hr, Simon, Ja., Columbia University [New York], Obesity Research Center, The University of Tennessee [Knoxville], Department of Nutrition, Exercise and Sports [Copenhagen], Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Scripps Research Institute, Louisiana State University (LSU), Universidade de São Paulo (USP), Centre hospitalier universitaire de Nantes (CHU Nantes), University of Calgary, University College Dublin (UCD), Instituto Mexicano del Seguro Social [Mexico City, Mexico] (IMSS), Novo Nordisk, Department of Obesity and Endocrinology, University of Liverpool, Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., Le Roux, Carel W., Ortiz, Rafael Violante, Jensen, Christine Bjørn, Wilding, John P.H., the SCALE Obesity and Prediabetes NN8022-1839 Study Group [.., Marchesini, Giulio, ], Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D., le Roux, C., Violante Ortiz, R., Jensen, C., Wilding, J. COLLABORATORS: amann A, Barakat A, Blüher M, Linn T, Mölle A, Segner A, Stübler P, Tosch-Sisting R, Pacini F, Santini F, Marchesini G, Rotella CM, Invitti C, Vettor R, Buscemi S, and Raya PM, Freijoo FC, de Barbará RG, Carraro R, Bobillo ER, de la Cuesta C, Farsang C, Csaszar A, Zahorska-Markiewicz B, Pupek-Musialik D, Franek E, Ostrowska L, Olszanecka-Glinianowicz M, Lalic N, Micic D, Ludvik B, Paulweber B, Prager R, Scheen A, Van Gaal L, Astrup AV, Hermansen K, Madsbad S, Rissanen A, Nieminen S, Savolainen M, Krempf M, Romon M, Laville M, Marre M, Mira R, Finucane F, Veenendaal A, van Berkum F, Johannsson-Vidarsdóttir S, Van de Walle V, Meesters E, Hjelmesæth J, Klemsdal TO, Kulseng B, Bach-Kliegel B, Laederach K, Villiger L, Golay A, Bilz S, Sathyapalan T, Bain S, Kumar S, Le Roux CW, Lean ME, McGowan B, Rehman T, Wilding J, Wittert G, Caterson I, Proietto J, Prins J, Geloneze Neto B, Gross JL, Chacra AR, Halpern A, Suplicy Hde A, Chow FC, Thacker HP, Chadha M, Chandalia H, Unnikrishnan A, Kalra S, Deshpande N, Shunmugavelu M, Deshmukh VC, Maislos M, Lieberman GS, Shimon I, Stern N, Nabriski D, Karnieli E, Shehadeh N, Gonzalez-Galvez G, Arechavaleta-Granell Mdel R, Violante Ortiz RM, Franco GM, Gurieva I, Suplotova LA, Troshina E, Ruyatkina LA, Voychik EA, Martsevich S, Startseva MA, Seeber ME, Badat A, Ellis G, Altuntas Y, Guler S, Ulgen E, Delibasi T, Chetty T, Hart R, Janzen J, Labonte I, Lau D, Liutkus J, O'Keefe D, Padwal R, Ransom TP, Tytus R, Weisnagel SJ, Adler J, Aqua K, Aronoff SL, Bedel GW, Blevins TC, Blumenau J, Brockmyre AP, Call RS, Canadas R, Chaykin LB, Cohen K, Conrow JK, Davis MG, Downey HJ, Drosman SR, Duckor S, Farmer H, Farrell J, Fehnel S, Finneran MP, Forbes R, Forker A, Fredrick M, Fujioka K, Geller SA, Gill S, Glaser L, Greco SN, Greenway FL, Harper W, Herman L, Hoekstra J, Ingebretsen R, Ison R, Jain RK, Kaplan R, Kaster SR, Haase GA, Kerzner B, Kirstein JL, Koltun W, Krieger DR, Lewis CE, Madder R, Marple RN, McDermott EJ, Mello CJ, Miller AB, Mullen J, Nardandrea J, O'Neil P, Pi-Sunyer F, Pucillo RM, Rhee C, Redrick S, Pardini A, Rothman J, Rubino DM, Sellers G, Smith T, Byars WD, Soufer J, Sussman AM, Patrick K, Schramm EL, Van Cleeff M, Berg SR, Wyatt HR, Simon JA.

Subjects
Blood Glucose, Counseling, Male, Type 2 diabetes, law.invention, Body Mass Index, Randomized controlled trial, Weight loss, law, Glucagon-Like Peptide 1, Weight management, Subcutaneous, Medicine (all), Reducing, Nausea, General Medicine, Middle Aged, Combined Modality Therapy, 3. Good health, Female, type 2 diabetes, medicine.symptom, Human, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Diet, Reducing, Injections, Subcutaneous, Injections, Subcutaneou, Placebo, Injections, Double-Blind Method, Internal medicine, Weight Loss, medicine, Humans, Hypoglycemic Agents, Obesity, Exercise, Hypoglycemic Agent, Liraglutide, business.industry, medicine.disease, Weight Lo, Diet, Endocrinology, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Body mass index, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Dyslipidemia
Abstract

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS: At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P

Published
2015
Full Text
View/download PDF

3. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

Author

James, Wp, Caterson, Id, Coutinho, W, Finer, N, VAN GAAL LF, Maggioni, Ap, TORP-PEDERSEN, C, Sharma, Am, Shepherd, Gm, Rode, Ra, Renz, Cl, Van Gaal LF, Torp-Pedersen, C, Pepine, C, Pocock, S, Drexler, H, Swedberg, K, Sleight, P, Armstrong, P, Kerr, D, Dagenais, G, Brophy, J, Avezum, A, Bogaty, P, Fabbri, G, Galli, M, Hildebrandt, P, Mann, J, Ostergren, J, Sherman, D, Zannad, F, Colquhoun, D, Hollanders, G, e Forti A, Costa, Cifkova, R, Toubro, S, Ziegler, O, Scherbaum, Wa, Jordan, J, Halmy, L, Ferrannini, E, Santini, F, Gonzalez, C, Narkiewicz, K, Hancu, N, Payer, J, Pascual, J, Wilding, J, Campbell, L, Carey, D, Gerstman, M, Karrasch, J, Lefkovits, J, Marks, J, Marks, S, Moses, R, Phillips, P, Proietto, J, Roberts, D, Roberts-Thomson, P, Shaw, J, Simpson, R, Singh, B, Singleton Jeffries, W, Stuckey, B, Boland, J, Brohet, C, Coucke, F, Dendale, P, Jouret, G, Kolanowski, J, Kutnowski, M, Martens, F, Muls, E, Peiffer, F, Penninckx, H, Scheen, A, Schoors, D, Vaerenberg, M, Van Cleemput, J, Van Crombrugge, P, Van Kuyk, M, Verhaegen, A, Wollaert, B, de Albuquerque DC, Appolinario, J, de Godoy Matos AF, Gross, Jl, Halpern, A, Kerr Saraiva JF, Milagres, R, Repetto, G, Suplicy, Hl, Zanella, Mt, Bednarova, J, Cepelak, V, Cerny, P, Hainer, V, Havranek, P, Homza, M, Jansa, P, Karlicek, M, Kolesar, J, Kotik, I, Kucera, D, Kuchar, J, Kunc, M, Kvapil, M, Linhart, A, Machova, V, Matuska, J, Oral, I, Pavlas, J, Pesatova, S, Povolny, J, Semrad, B, Smetana, K, Soucek, M, Svacina, S, Tesinsky, P, Urbanek, R, Wasserburger, B, Zachoval, R, Zahumensky, E, Zidkova, E, Astrup, A, Dominguez, H, Faber, J, Hilderbrant, P, Kober, L, Perrild, H, Richelsen, B, Sogaard, P, Svendsen, Ol, Urhammer, S, Archambeaud, F, Basdevant, A, Borys, Jm, Bringer, J, Brunetiere, C, Charpentier, G, Cocaul-André, M, Dabadie, H, Dubreuil, A, Estour, B, Gautier, Jf, Gibault, T, Halimi, S, Hespel, Jp, Issa Sayegh, M, Krempf, M, Laville, M, Lecerf, Jm, Louvet, Jp, Penfornis, A, Ritz, P, Schlienger, Jl, Schmitt, B, Valensi, P, Baar, M, Beermann, J, Bock, M, Boenner, G, Dammann, Hg, Diehm, C, Ditschuneit, H, Gadow, J, Gehlhar, S, Gessner, S, Guthersohn, A, Hamann, A, Hanefeld, M, Hasenfuss, G, Herzner, A, Heun, Kc, Heufelder, Ae, Hohensee, H, Jacob, S, Krings, P, Krätzig, B, Krosse, B, Lehmann, Rt, Mindt-Prüfert, S, Maisch, B, Pfeiffer, Af, Richard, F, Rose, B, Schmidt, E, Scholze, J, Schreckenberg, A, Stuebler, P, Walter, J, Wirth, A, Wunderlich, J, Abraham, G, Altorjay, A, Augusztin, G, Csaszar, A, Czuriga, I, Dinnyes, J, Gero, L, Gyimesi, A, Janosi, A, Kovacs, I, Liziczai, I, Majtenyi, A, Medvegy, M, Nadhazi, Z, Pados, G, Polak, G, Ronaszeki, A, Sido, Z, Simon, K, Anzà, C, Bevilacqua, M, Bosello, O, Chiariello, M, Cordera, R, Ferrari, E, Frittitta, L, Giorgino, R, Liuzzi, A, Malinverni, C, Di Mario, U, Melchionda, N, Occhi, G, Perticone, F, Pinchera, A, Pinelli, G, Rovera, G, Santeusanio, F, Urbinati, S, Alpizar-Salazar, M, Carrillo-Ortega, E, Fanghanel Salmon, G, Laviada-Molina, Ha, Madero, Ma, Rodriguez, G, Saldate, C, Sanchez-Castillo, Cp, Violante, Rm, Wacher, N, Zayas-Jaime, Fj, Zuniga-Guajardo, S, Adamiec, R, Banasiak, W, Chrusciel, P, Derlaga, B, Gebala, A, Gessek, J, Janik, K, Janion, M, Kalina, Z, Kozlowski, A, Kusnierz, B, Majcher, Z, Miekus, P, Niegowska, J, Okopien, B, Ostrowska, L, Pasowicz, M, Piepiorka, M, Pluta, W, Polaszewska-Muszynska, M, Ponikowski, P, Pupek-Musialik, D, Sawicki, A, Sobocik, H, Stankiewicz, A, Szpajer, M, Trojnar, R, Tykarski, A, Wrabec, K, Wyrzkowski, B, Zahorska-Markiewicz, B, Zalewski, M, Carrageta, M, Mendes Pedro MM, Parente Martins LM, dos Santos, L, Babes, A, Creteanu, G, Dan, Ga, Dragulescu, Si, Graur, M, Tirgoviste, Ci, Morosanu, M, Mota, M, Paveliu, Fs, Radoi, M, Ranetti, A, Totoian, I, Andre, I, Bugan, V, Cencarik, J, Csala, L, Farsky, S, Gonsorcik, J, Kamensky, G, Kmec, J, Krahulec, B, Kurian, R, Macek, V, Majercak, I, Micko, K, Mokan, M, Riecansky, I, Sojka, G, Uhliar, R, Urgeova, L, Vancik, J, Baro, Fm, Barrios Merino, A, Borras, Jl, Caixas, A, Cuatrecasas Cambra, G, Dominguez Escribano JR, Duran Garcia, S, Escobar-Jimenez, L, Esteva de Antonio, I, Formiguera Sala, X, Garcia-Luna, Pp, Garcia Robles, R, Gonzalez Albarran, O, Hernandez-Mijares, A, Martin Hidalgo, A, Masmiquel Comas, L, Morales Perez, F, Moreno Esteban, B, Pascual Izuel JM, Redon Mas, J, Ricart, W, Rubio, Ma, Ruilope, Lm, Salas-Salvado, J, Terroba Larumbe, M, Tinahones, F, de la Torre Casares ML, Vidal Cortada, J, Zuniga-Perez Lemaur, M, Abdulhakim, Ee, Adler, A, Barnett, Ah, Bodmer, C, Campbell, Iw, Chowdhury, T, Cleland, J, Cook, Rc, Dinneen, S, Donnachie, H, Haslam, Dw, Hillis, Gs, Horne, M, Howarth, Dj, Hughes, E, Jackson, S, Jones, Sc, Jones, Th, Kumar, S, Lean, M, Maroni, J, Mcinnes, G, Middleton, A, Morris, A, Newcombe, G, O'Kane, Kp, Pavel, Ic, Pawa, R, Perry, C, Pitts, C, Raja, A, Reckless, J, Robinson, J, Sarmiento, R, Soo, Sc, Taylor, S, Thomas, Ho, Thomson, Ma, and Wilkins, M.

Subjects
Male, medicine.medical_specialty, Myocardial Infarction, Blood Pressure, Kaplan-Meier Estimate, Type 2 diabetes, Klinikai orvostudományok, Placebo, law.invention, Double-Blind Method, Randomized controlled trial, Weight loss, law, Internal medicine, Appetite Depressants, medicine, Humans, Obesity, Myocardial infarction, Stroke, Aged, business.industry, Hazard ratio, Orvostudományok, General Medicine, Middle Aged, Overweight, medicine.disease, Surgery, Diabetes Mellitus, Type 2, Cardiovascular Diseases, Cardiology, Female, Human medicine, medicine.symptom, business, Cyclobutanes, Sibutramine, medicine.drug
Abstract

Background The long-term effects of sibutramine treatment on the rates of cardiovascular events and cardiovascular death among subjects at high cardiovascular risk have not been established. Methods We enrolled in our study 10,744 overweight or obese subjects, 55 years of age or older, with preexisting cardiovascular disease, type 2 diabetes mellitus, or both to assess the cardiovascular consequences of weight management with and without sibutramine in subjects at high risk for cardiovascular events. All the subjects received sibutramine in addition to participating in a weight-management program during a 6-week, single-blind, lead-in period, after which 9804 subjects underwent random assignment in a double-blind fashion to sibutramine (4906 subjects) or placebo (4898 subjects). The primary end point was the time from randomization to the first occurrence of a primary outcome event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death). Results The mean duration of treatment was 3.4 years. The mean weight loss during the lead-in period was 2.6 kg; after randomization, the subjects in the sibutramine group achieved and maintained further weight reduction (mean, 1.7 kg). The mean blood pressure decreased in both groups, with greater reductions in the placebo group than in the sibutramine group (mean difference, 1.2/1.4 mm Hg). The risk of a primary outcome event was 11.4% in the sibutramine group as compared with 10.0% in the placebo group (hazard ratio, 1.16; 95% confidence interval [CI], 1.03 to 1.31; P=0.02). The rates of nonfatal myocardial infarction and nonfatal stroke were 4.1% and 2.6% in the sibutramine group and 3.2% and 1.9% in the placebo group, respectively (hazard ratio for nonfatal myocardial infarction, 1.28; 95% CI, 1.04 to 1.57; P=0.02; hazard ratio for nonfatal stroke, 1.36; 95% CI, 1.04 to 1.77; P=0.03). The rates of cardiovascular death and death from any cause were not increased. Conclusions Subjects with preexisting cardiovascular conditions who were receiving long-term sibutramine treatment had an increased risk of nonfatal myocardial infarction and nonfatal stroke but not of cardiovascular death or death from any cause. (Funded by Abbott; ClinicalTrials.gov number, NCT00234832.)

Published
2010
Full Text
View/download PDF

4. How should we assess the clinical relevance of guidelines in primary health care?

Author

Lech Mm and Ostrowska L

Subjects
medicine.medical_specialty, business.industry, Public health, Public Health, Environmental and Occupational Health, Medical guideline, Pharmacotherapy, Family medicine, Health care, Epidemiology, medicine, Observational study, business, Quality circle, Health policy
Abstract

Experiences from disseminating guidelines for pharmacotherapy in “quality circles”. To assess the “clinical relevance” of the guidelines, 142 GPs participating in 8 quality circles supplied by the Kassenarztliche Vereinigung Hesse (Association of Statutory Health Insurance Physicians) were continually interviewed by questionnaires administered in the circles. The findings of the survey of the participants had to be reviewed by the authors of the guidelines. A total of 142 physicians (GPs) participating in a structured advanced training for pharmacotherapy were continuously interviewed from 2001–2003 by a questionnaire. They were asked which of the 135 recommendations selected from the 8 guidelines they had used in practice. The results of the survey were later presented to the 15 authors of the guidelines who had also been acting as moderators of the quality circles. As “peers” they were asked by questionnaire to review the findings and to judge which of the recommendations they themselves estimated as “essential”, “important” or “non-essential” to the success of the therapy. As “acceptance” of a recommendation by the participants we defined: “used in practice ?”=”yes”. The rate of “acceptance” varied widely and four groups of almost equal rate of acceptance could be identified: recommendations that had been applied in 90–100% were classified as “very high”, 75–89% as “high”, 50–75% as “problematic” and less than 50% as “very low” acceptance. The reviewers evaluated almost all of the recommendations that had been applied by the participants in a high or very high rate as “essential” or “important”. On the other hand the reviewers estimated almost half of the recommendations with a “very low” rate of acceptance as “non-essential” (40%) or made no answer (7%). With respect to the 31 recommendations with problematic application on the side of the participants, among the reviewers a consent evaluating them as “essential” or “important” or “non-essential” for therapy existed only for 8 (26%). The implementation of guidelines in quality circles does not assure a high rate of compliance with recommendations on the side of the target group. Authors of guidelines should recognize their latent reservations with respect to the relevance of their own recommendations. Evaluation of the compliance with guidelines should consider that not every recommendation claims the same grade of relevance. Estimating the relevance of a given recommendation seems to be an indispensable but neglected task of implementation.

Published
2004
Full Text
View/download PDF

6. Effect of L-arginine supplementation on insulin resistance and serum adiponectin concentration in rats with fat diet

Author

Miczke, A., Suliburska, J., Pupek-Musialik, D., Ostrowska, L., Anna Jabłecka, Krejpcio, Z., Skrypnik, D., and Bogdański, P.

Subjects
Original Article
Abstract

Object: The purpose of this study was to determine whether supplementation with L-arginine, a substrate used in the production of nitric oxide, had an effect on adiponectin concentration in rats fed a high-fat diet. The influence of L-arginine on insulin resistance was also evaluated. Materials and methods: The experiment was performed using 36 Wistar rats divided into three groups: group 1 was fed a standard diet, group 2 a high-fat (HF) diet, group 3 a HF diet supplemented with L-arginine. After 42 days, serum levels of lipids, glucose, insulin, NO, and adiponectin were measured. Insulin resistance (IR) was estimated by the Homeostasis Model Assessment (HOMA). Results: Body mass was equal in all 3 groups, at the beginning as well as at the end of the study, however, in group 2 the amount of visceral fat was greater after 42 days. In group 3, there was a tendency for visceral fat to decrease. An increase in cholesterol, triglycerides, insulin and HOMA-IR, as well as a decrease in NO and adiponectin were seen in group 2, while in group 3, L-arginine supplementation ameliorated these disturbances. Conclusions: Our study shows that L-arginine supplementation in rats fed a HF diet is associated with an increase in insulin sensitivity. Our findings suggest that the underlying mechanism could be at least partially related to an increase in adiponectin concentration.

9. The assessment of the nutritional value of meals consumed by patients with recognized schizophrenia

Author

Stefańska, E., Wendołowicz, A., Lech, M., Wilczyńska, K., Beata Konarzewska, Zapolska, J., and Ostrowska, L.

Subjects
Adult, Dietary Fiber, Male, Nutritional Status, lcsh:TX341-641, lcsh:RC963-969, Food Preferences, Young Adult, Sex Factors, Dietary Carbohydrates, Humans, nutritional value of meals, lcsh:Public aspects of medicine, digestive, oral, and skin physiology, lcsh:RA1-1270, Feeding Behavior, nutritional habit, Middle Aged, Nutrition Surveys, Dietary Fats, Diet, Case-Control Studies, lcsh:Industrial medicine. Industrial hygiene, Schizophrenia, Female, lcsh:Nutrition. Foods and food supply, Attitude to Health, Nutritive Value
Abstract

Background. As studies show, changes in diet - so important in the therapy of psychiatric disorders and related to changes in appetite and nutritional preferences, including avoiding of the consumption of specific groups of products and dishes - are much more frequent among patients affected by schizophrenia. Objective. The aim of the study was to assess the chosen nutritional habits, including the number and type of meals usually consumed during a day, snacking between meals and the energy value and content of the chosen nutrients in the diets of persons with recognized schizophrenia. Material and methods. The study was carried out in a group of 85 patients with recognized schizophrenia, and 70 healthy volunteers ranging in age from 18-65 years without mental or nutritional disorders. For the purpose of the study, we used a questionnaire containing questions on nutritional habits. A 24-hour diet recall was used in the quantitative nutritional assessment with the use of the computer program Dieta 5.0. Results. Female patients with recognized schizophrenia were having 3 meals a day significantly more frequently as compared to healthy women. They were also having an afternoon snack much more frequently as compared to the control group. The food rations of female patients were characterized by a significantly higher energy value and the content of most of the assessed nutrients as compared to the food rations of healthy women. The food rations of men with recognized schizophrenia were characterized by a much lower energy intake and the content of the majority of assessed nutrients as compared to the food rations of healthy men. In all compared groups, we observed an energetic structure of food rations with the breakdown by specific meals that was inconsistent with the applicable recommendations. Conclusions. Despite of differences between the nutritional value of the meals of patients with recognized schizophrenia and those of healthy subjects, it seems advisable to involve patients with recognized schizophrenia in the education of forming appropriate nutritional habits.

Catalog

Books, media, physical & digital resources
See catalog results